KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Other Non-Current Assets (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Other Non-Current Assets for 16 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 1.66% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.0 million through Dec 2025, up 1.66% year-over-year, with the annual reading at $2.0 million for FY2025, 1.66% up from the prior year.
  • Other Non-Current Assets hit $2.0 million in Q4 2025 for Inovio Pharmaceuticals, roughly flat from $2.0 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $25.9 million in Q1 2021 to a low of $566415.0 in Q3 2024.
  • Historically, Other Non-Current Assets has averaged $2.4 million across 5 years, with a median of $1.0 million in 2022.
  • Biggest five-year swings in Other Non-Current Assets: surged 943.59% in 2021 and later crashed 95.08% in 2022.
  • Year by year, Other Non-Current Assets stood at $1.4 million in 2021, then tumbled by 52.02% to $684044.0 in 2022, then dropped by 11.51% to $605315.0 in 2023, then soared by 227.05% to $2.0 million in 2024, then grew by 1.66% to $2.0 million in 2025.
  • Business Quant data shows Other Non-Current Assets for INO at $2.0 million in Q4 2025, $2.0 million in Q3 2025, and $2.0 million in Q2 2025.